Cutler R
Am J Cardiol. 1983 Feb 24;51(4):628-31. doi: 10.1016/s0002-9149(83)80199-4.
Diuretics and adrenergic blocking agents have been used extensively in the treatment of hypertension. Recent studies have indicated that the thiazides and chlorthalidone have an adverse effect on lipid metabolism, by increasing plasma triglycerides, total cholesterol, and low density lipoprotein cholesterol in mildly hypertensive patients. These same agents produced little change in high density lipoprotein cholesterol. On the other hand, the loop diuretic furosemide adversely affected the cholesterol ratio by lowering high density lipoproteins (HDL) instead of increasing very low density lipoproteins (VLDL) or low density lipoproteins (LDL). The centrally acting drug methyldopa has also been reported to lower HDL, while another centrally acting drug, reserpine, appears to be lipid-neutral. Practically all the beta blocking agents increase triglycerides or decrease HDL, thus yielding an adverse cholesterol ratio. The alpha 1-adrenergic blocking agent prazosin has been shown in several studies to have no adverse effect on the lipid profile.
利尿剂和肾上腺素能阻滞剂已被广泛用于治疗高血压。最近的研究表明,噻嗪类药物和氯噻酮对脂质代谢有不良影响,可使轻度高血压患者的血浆甘油三酯、总胆固醇和低密度脂蛋白胆固醇升高。这些药物对高密度脂蛋白胆固醇几乎没有影响。另一方面,袢利尿剂呋塞米通过降低高密度脂蛋白(HDL)而不是增加极低密度脂蛋白(VLDL)或低密度脂蛋白(LDL)来对胆固醇比例产生不利影响。中枢作用药物甲基多巴也有报道可降低HDL,而另一种中枢作用药物利血平似乎对脂质无影响。几乎所有的β受体阻滞剂都会增加甘油三酯或降低HDL,从而产生不利的胆固醇比例。多项研究表明,α1肾上腺素能阻滞剂哌唑嗪对血脂谱没有不良影响。